Search

Background Red clover is an important source of isoflavones; which has been made commercially available as dietary supplements for the treatment of menopausal symptoms. Bioavailability and metabolism of these red clover isoflavones (RCI) have not been studied in detail. Fructooligosaccharides (FOS) stimulate the growth of intestinal bacteria and play an important role in the formation of certain isoflavone metabolites, such as equol and O -desmethylangolensin. Objective To determine the bioavailability of RCI metabolites and analyse whether FOS supplementation could influence their bioavailability. Methods Seventeen healthy adults were enrolled in the study carried out in two periods. In the first, compound bioavailability was determined after consumption of 80 mg of RCI (MF11RCE). In the second, a 6-day supplementation of 2 × 3000 mg/day of FOS was administered before isoflavone consumption. Results Biochanin A and formononetin were rapidly absorbed and both reached maximum concentrations at an average of 5–7 h. Demethylation was a major reaction in the metabolic pathway. Daidzein serum level peaked after about 12.6 h. Supplementation with FOS led to a significant decrease in the bioavailability of daidzein, dihydroformononetin, dihydrogenistein and dihydrodaidzein. An increase in equol production was also observed which did not reach statistical significance ( p > 0.05). Conclusion This study is the first to provide detailed data on RCI bioavailability in humans and determine no influence of FOS yet a trend toward increased equol production. More research is warranted involving a greater sample size. [ABSTRACT FROM AUTHOR]

Abstract: Red clover extracts contain a variety of isoflavones, which have affinity toward estrogen receptor alpha (ERα), estrogen receptor beta (ERβ), androgen receptor (AR), and progesterone receptor (PR). Upon ingestion, they undergo various metabolic transformations. For a complete evaluation of red clover extracts and possible health benefits, the resulting metabolites should also be investigated. Biochanin A, formononetin, genistein, daidzein, dihydrobiochanin A, dihydroformononetin, dihydrogenistein, dihydrodaidzein, 3′-hydroxygenistein, 6-hydroxydaidzein, 6-hydroxydesmethylangolensin, equol, O-desmethylangolensin, angolensin, and p-ethylphenol were tested for their transactivation potential toward ERα, AR, and PR in yeast. Competitive binding assays with radiolabeled 17β-estradiol, 17α-methyltrienolone or progesterone assessed binding to the respective ERα and ERβ, AR, and PR. The compounds showed only weak binding affinity to AR and PR, with IC50 values being greater (i.e., lesser affinity) than 10−5 M for the respective receptor. So far, beneficial health effects have been attributed to the production of equol. We propose that other metabolites can also contribute to these effects. However, more detailed information for the formation of these metabolites in humans and for bioavailability data are required to confirm our assumptions. [Copyright &y& Elsevier]